Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of September 30, 2024, Alexandria has a total market capitalization of $33.1 billion and an asset base in North America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

Alexandria Real Estate Equities Inc.

In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $72.00. T...

Ultragenyx Pharmaceutical (RARE) Receives a Buy from J.P. Morgan

The latest announcement is out from Mare Engineering Group SpA ( ($IT:MARE) ). Mare Group S.p.A., an engineering company listed on Euronext Growth ...

Mare Group Increases Treasury Share Holdings Under Ongoing Buyback Programme

Daré Bioscience (($DARE)) has held its Q1 earnings call. Read on for the main highlights of the call. Daré Bioscience’s latest earnings call struck...

Daré Bioscience Nears First Revenues Amid Cash Squeeze

Ultragenyx Pharmaceutical, Inc. (($RARE)) has held its Q1 earnings call. Read on for the main highlights of the call. Ultragenyx Pharmaceutical’s l...

Ultragenyx Earnings Call Balances Growth and Cash Burn

The latest announcement is out from Daré Bioscience ( ($DARE) ). Daré Bioscience, Inc. completed the closings of its previously announced Regulatio...

Daré Bioscience Completes Regulation A Investor Unit Offering

Ultragenyx Pharmaceutical ( ($RARE) ) has issued an announcement. At its Annual Meeting of Stockholders held on May 14, 2026, Ultragenyx Pharmaceut...

Ultragenyx Shareholders Approve Incentive Plan, Elect Directors

Alexandria Equities ( ($ARE) ) has shared an announcement. On May 13, 2026, Alexandria Real Estate Equities, Inc. held its 2026 Annual Meeting of S...

Alexandria Equities Stockholders Approve Directors and Key Proposals

There’s a lot to be optimistic about in the Financial sector as 3 analysts just weighed in on Citizens Financial (CFG), Ares Management (ARES) and ...

Analysts Offer Insights on Financial Companies: Citizens Financial (CFG), Ares Management (ARES) and Credicorp (BAP)

Mare Engineering Group SpA ( ($IT:MARE) ) has provided an update. Mare Group’s board has approved the launch of a treasury share buyback and dispos...

Mare Group Launches Buyback Plan and Confirms Stock Plan Targets

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kodiak Sciences (KOD), IN8bio (INAB) and Ultragenyx ...

Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD), IN8bio (INAB) and Ultragenyx Pharmaceutical (RARE)

RBC Capital analyst Sabahat Khan maintained a Hold rating on Aecon Group Inc. yesterday and set a price target of C$49.00. According to TipRanks, K...

RBC Capital Keeps Their Hold Rating on Aecon Group Inc. (ARE)

American Rebel Holdings ( ($AREB) ) has shared an update. American Rebel Holdings significantly restructured parts of its capital stack between Apr...

American Rebel Executes Equity-for-Debt Capital Restructuring Transactions

In a report released today, Eliana Merle from Barclays maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $43.00. Merle c...

Barclays Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alphatec Holdings (ATEC) and Ultragenyx Pharmaceutic...

Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC) and Ultragenyx Pharmaceutical (RARE)

There’s a lot to be optimistic about in the Financial sector as 3 analysts just weighed in on Axis Capital (AXS), KeyCorp (KEY) and Ares Management...

Analysts Offer Insights on Financial Companies: Axis Capital (AXS), KeyCorp (KEY) and Ares Management (ARES)

There’s a lot to be optimistic about in the Financial sector as 3 analysts just weighed in on Fifth Third Bancorp (FITB), Ares Management (ARES) an...

Analysts Offer Insights on Financial Companies: Fifth Third Bancorp (FITB), Ares Management (ARES) and Heritage Insurance Holdings (HRTG)

Barclays analyst Benjamin Budish maintained a Buy rating on Ares Management on May 1 and set a price target of $140.00. The company’s shares closed...

Barclays Remains a Buy on Ares Management (ARES)

Ares Management Lp (($ARES)) has held its Q1 earnings call. Read on for the main highlights of the call. Ares Management struck an upbeat tone on i...

Ares Management Earnings Call Highlights Broad-Based Growth

An update from Carter Bankshares ( ($CARE) ) is now available. Carter Bankshares, Inc. has released an updated first-quarter 2026 investor presenta...

Carter Bankshares Reinstates Dividend and Highlights Growth

Carter Bankshares ( ($CARE) ) has provided an update. On May 1, 2026, Carter Bankshares, Inc., the holding company for Carter Bank & Trust, complet...

Carter Bankshares Divests Bearing Insurance Group Stake

In a report released today, Chris Murray from ATB Cormark Capital Markets maintained a Hold rating on Aecon Group Inc., with a price target of C$49...

Aecon Group Inc. (ARE) Gets a Hold from ATB Cormark Capital Markets

In a report released today, from National Bank maintained a Buy rating on Aecon Group Inc., with a price target of C$59.00. In addition to National...

National Bank Reaffirms Their Buy Rating on Aecon Group Inc. (ARE)

Desjardins analyst maintained a Hold rating on Aecon Group Inc. today and set a price target of C$52.00. In addition to Desjardins, Aecon Group Inc...

Aecon Group Inc. (ARE) Receives a Hold from Desjardins

An announcement from Mare Engineering Group SpA ( ($IT:MARE) ) is now available. Mare Group S.p.A., an engineering and technology firm listed on Eu...

Mare Group Approves 2025 IFRS Accounts, Dividend and Higher Board Pay Amid Rising Debt

Shares in Blackstone ($BX), the world’s largest alternative asset manager, barely moved on Wednesday after new filings showed that demand for its f...

Blackstone Stock (BX) Flat as Investor Appetite for Flagship Fund Wanes

Companies in the Financial sector have received a lot of coverage today as analysts weigh in on Northwest Bancshares (NWBI), Ares Management (ARES)...

Analysts Offer Insights on Financial Companies: Northwest Bancshares (NWBI), Ares Management (ARES) and Renaissancere Holdings (RNR)

In a report released on April 27, Sabahat Khan from RBC Capital maintained a Hold rating on Aecon Group Inc., with a price target of C$44.00. The c...

RBC Capital Remains a Hold on Aecon Group Inc. (ARE)

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on Ares Management (ARES) and Erie Indemnity Company (ER...

Analysts Are Bullish on Top Financial Stocks: Ares Management (ARES), Erie Indemnity Company (ERIE)

An update from Arecor Therapeutics PLC ( ($GB:AREC) ) is now available. Arecor Therapeutics has released its Annual Report and Accounts for the yea...

Arecor Posts 2025 Annual Report and Sets Hybrid-Access AGM

Analysts have been eager to weigh in on the Real Estate sector with new ratings on Lineage, Inc. (LINE), Brixmor Property (BRX) and Alexandria Equi...

Analysts’ Opinions Are Mixed on These Real Estate Stocks: Lineage, Inc. (LINE), Brixmor Property (BRX) and Alexandria Equities (ARE)

There’s a lot to be optimistic about in the Real Estate sector as 2 analysts just weighed in on Alexandria Equities (ARE) and Scentre Group (STGPF)...

Analysts Offer Insights on Real Estate Companies: Alexandria Equities (ARE) and Scentre Group (OtherSTGPF)

Shares in X-Energy ($XE), the Amazon ($AMZN)-backed small modular reactor (SMR) developer, extended their Friday market-debut jump by adding anothe...

Current Quarter	$1.64	Next Quarter	$1.53
Current Year	$6.4	Next Year	$5.93
QoQ Growth	-6.7%	YoY Growth	-7.3%
3Y EPS CAGR	-100.0%	Target Price	$51.93
Consensus	Buy	Upside	+7.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARE	$48.47	+0.21%	1.24M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARE	$48.47	+0.2%	1.24M
3
4
5
6

ARE

ARE

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Alexandria Real Estate Equities Inc. Data in Excel

Get Alexandria Real Estate Equities Inc. Data in Excel